Anti-AIDS drugs reduce the risk of comorbidities in HIV-infected patients

AIDS is one of the major challenges threatening global public health
.

Merck China announced on June 11 that its daily single-tablet compound preparation Destrol (DOR/3TC/TDF) and daily single-table single-drug preparation Pedro (doravirin tablets) have been approved by the China National Medical Products Administration.
Approved to be officially listed in China for the treatment of adult HIV-1 virus infection
.

Professor Li Taisheng, director of the Department of Infectious Diseases of the Chinese Academy ofMedical Sciences /Peking Union Medical College Hospital and chairman of the Infectious Diseases Branch of the Chinese Medical Association , said, “With the advancement of medicine, the continuous emergence of new drugs has extended the life expectancy of HIV-infected people, and AIDS has gradually become a kind of disease.
control of chronic diseases .
in the process of long-term management of the disease, to cardiovascular disease as the representative of all kinds of complications has become an important factor affecting life expectancy and quality of life of patients, so doctors and patients in need of enhancement of dyslipidemia and weight gain The attention to the problem should be given priority when choosing treatment options.
The listing of Destro and Pedro have provided us with more options to deal with the complex challenges posed by HIV infection .
"

Tian Anna, President of Merck China, said, “In China, Merck has always been committed to supporting the Chinese government's anti-AIDS work
.